Geburtshilfe Frauenheilkd 2015; 75(09): 935-940
DOI: 10.1055/s-0035-1557905
Original Article
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial

Sentinel-Lymphknoten-Detektion beim Mammakarzinom mittels Fluoreszenztechnik – eine Alternative zum Technetiumverfahren?
E.-M. Grischke
Universitäts-Frauenklinik Tübingen, Tübingen
,
C. Röhm
Universitäts-Frauenklinik Tübingen, Tübingen
,
M. Hahn
Universitäts-Frauenklinik Tübingen, Tübingen
,
G. Helms
Universitäts-Frauenklinik Tübingen, Tübingen
,
S. Brucker
Universitäts-Frauenklinik Tübingen, Tübingen
,
D. Wallwiener
Universitäts-Frauenklinik Tübingen, Tübingen
› Author Affiliations
Further Information

Publication History

received 11 February 2014
revised 25 June 2015

accepted 25 June 2015

Publication Date:
07 October 2015 (online)

Abstract

Introduction: Detection of sentinel lymph nodes (SLN) is the standard procedure to evaluate axillary lymph node status in breast cancer. In addition to known and established procedures such as the blue dye method and scintigraphy, this study investigated the efficacy of a method based on use of the fluorescent dye indocyanine green (ICG). Patients and Method: A total of 126 women with breast cancer histologically verified by punch biopsy were studied during surgical removal of SLN. In addition to SLN marking with technetium and scintigraphy, intra-individual comparison was done using indocyanine green (ICG) for marking instead of the standard blue dye. Results: Scintigraphy had a detection rate of 96 %; the detection rate with ICG was just under 89 %. A body mass index (BMI) > 40 was found to be a limiting factor for the fluorescent method. Investigation into potential toxicities associated with the use of the fluorescent dye ICG revealed no systemic or even local side effects. The fluorescent method was found to be significantly less expensive than the scintigraphy method. Conclusion: The ICG fluorescence technique for the detection of SLN was found to be a valid and feasible method in clinical practice when compared directly with the blue dye method and scintigraphy.

Zusammenfassung

Einleitung: Die Detektion des Sentinel-Lymphknotens (SLN) ist mittlerweile ein Standardverfahren zur Erfassung des axillären Lymphknotenstatus beim Mammakarzinom. Neben den bekannten und etablierten Verfahren, wie der blauen Farbstoffmethode und dem szintigrafischen Verfahren, wurde in der vorliegenden Untersuchung die Aussagefähigkeit einer Methode überprüft, basierend auf dem Einsatz eines Fluoreszenzfarbstoffs in Form von Indocyaningrün (ICG). Patientinnen und Methoden: Untersucht wurden dabei insges. 126 Patientinnen mit durch Stanzbiopsie histologisch gesichertem Mammakarzinom im Rahmen der operativen Entfernung des SLN. Neben einer standardmäßigen szintigrafischen Markierung des SLN mittels Technetium erfolgte im intraindividuellen Vergleich anstelle der üblichen Blaumarkierung die Markierung mittels Indocyaningrün (ICG). Ergebnisse: Es konnte mit der Szintigrafie eine Detektionsrate von 96 % erreicht werden, mittels ICG eine Rate von knapp 89 %. Als limitierender Faktor für das Fluoreszenzverfahren erwies sich ein Body-Mass-Index > 40 (BMI > 40). Die Erfassung von möglicherweise auftretenden Toxizitäten bei Anwendung des Fluoreszenzfarbstoffs ICG ergab keinen Hinweis auf systemische oder auch lokale Nebenwirkungen. Im Kostenvergleich erweist sich die Fluoreszenztechnik als deutlich kostengünstiger als das szintigrafische Verfahren. Schlussfolgerung: Die SLN-Detektion mittels Fluoreszenzverfahren durch Einsatz von ICG erweist sich im klinischen Einsatz und direktem Vergleich zur blauen Farbstoffmethode und dem szintigrafischen Verfahren als valides und praktikables Verfahren.

 
  • References

  • 1 Fasching PA, Ekici AB, Wachter DL et al. Breast cancer risk – from genetics to molecular understanding of pathogenesis. Geburtsh Frauenheilk 2013; 73: 1228-1235
  • 2 Heywang-Koebrunner S, Bock K, Heindel W et al. Mammography screening – as of 2013. Geburtsh Frauenheilk 2013; 73: 1007-1016
  • 3 Sinn P, Aulmann S, Wirtz R et al. Multigene assays for classification, prognosis, and prediction in breast cancer: a critical review on the background and clinical utility. Geburtsh Frauenheilk 2013; 73: 932-940
  • 4 Lux MP, Maass N, Schütz F et al. Breast cancer 2013 – interpretation of new and known data. Geburtsh Frauenheilk 2013; 73: 584-598
  • 5 Hubalek M, Bartsch R, Gnant M et al. Axillary dissection in the case of positive sentinel lymph nodes: results of the Innsbruck Consensus Conference. Geburtsh Frauenheilk 2012; 72: 293-298
  • 6 Leitlinienprogramm Onkologie S3. Leitlinie Mammakarzinom. AWMF (Registernummer 032-045OL) Juli 2012.
  • 7 AGO Guidelines Breast Version 2014. Publiziert bei der AGO e. V... Online: http://www.ago-online.de/en/guidelines-mamma/march-2014/
  • 8 Lyman GH, Giuliano AE, Somerfield MR et al. American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703-7720
  • 9 Veronesi U, Paganelli G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553
  • 10 McMasters KM, Tuttle TM, Carlson DJ et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000; 18: 2560-2566
  • 11 Rubio I, Korourian S, Christopher C et al. Sentinel lymph node biopsy for staging breast cancer. Am J Surg 1998; 176: 532-537
  • 12 Krag D, Weaver D, Ashikaga T et al. The sentinel node in breast cancer— a multicenter validation study. N Engl J Med 1998; 339: 941-946
  • 13 Rubio I, Korourian S, Christopher C et al. Sentinel lymph node biopsy for staging breast cancer. Am J Surg 1998; 76: 532-537
  • 14 Hojo T, Nagao T, Kikuyama M et al. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. Breast 2010; 19: 210-213
  • 15 Purushotham AD, Macmillan RD, Wishart GC. Advances in axillary surgery for breast cancer – time for a tailored approach. Eur J Surg Oncol 2005; 31: 929-931
  • 16 Benson JR, Querci della Rovere G. Management of the axilla in women with breast cancer. Lancet Oncol 2007; 8: 331-348
  • 17 Motomura K, Inaji H, Komoike Y et al. Sentinel node biopsy guided by indocyanine green dye in breast cancer patients. Jap J Clin Oncol 1999; 29: 604-607
  • 18 Sugie T, Kassim KA, Takeuchi M et al. A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast cancer. Cancers (Basel) 2010; 2: 713-720
  • 19 Abe H, Umeda T, Mori M et al. Indocyanine green fluorescence imaging system for sentinel lymph node biopsy in early breast cancer patients. J Clin Oncol 2010; 28 (Suppl. 15) 6492
  • 20 Krag DN, Anderson J, Julian TB et al. Comparison of sentinel lymph node resection to conventional axillary dissection in clinically node negative breast cancer patients: primary outcome results of NSABP B032 trial. Lancet Oncol 2010; 11: 927-933
  • 21 Hirche C, Murawa D, Mohr Z et al. ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat 2010; 121: 373-378
  • 22 Tagaya N, Yamazaki R, Nakagawa A et al. Intraoperative identification of sentinel lymph nodes by near infra-red fluorescence imaging in patients with breast cancer. Am J Surg 2008; 195: 850-853
  • 23 Hünerbein M. Expert report on Indocyanine green (ICG) application for sentinel node detection by fluorescence. 2009. Mitteilung der Fa. Pulsion.
  • 24 Kitai T, Inomoto T, Miwa M et al. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer 2005; 12: 211-215
  • 25 Murawa D, Hirche C, Dresel S et al. Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br J Surg 2009; 11: 1289-1294
  • 26 Aoyama K, Kamio T, Ohchi T et al. Sentinel lymph node biopsy for breast cancer patients using fluorescence navigation with indocyanine green. World J Surg Oncol 2011; 9: 157
  • 27 Cody 3rd HS, Fey J, Akhurst T et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 2001; 8: 13-19
  • 28 Hirche C, Mohr Z et al. High rate of solitary sentinel node metastases identification by fluorescence-guided lymphatic imaging in breast cancer. J Surg Oncol 2011; 105: e162-e166
  • 29 Hojo T, Nagao T, Kikuyama M et al. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. Breast 2010; 210-213
  • 30 Ballardini B, Santoro L, Sangalli C et al. The indocyanine green method is equivalent to the 99mTc-labeled radiotracer method for identifying the sentinel node in breast cancer: a concordance and validation study. Eur J Surg Oncol 2013; 39: 1332-1336
  • 31 Polom K, Murawa D, Nowaczyk P et al. Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine green-human serum albumin in comparison with gamma emitting radioactive colloid tracer. Eur J Surg Oncol 2012; 38: 137-142
  • 32 Takeuchi M, Sugie T, Abdelazeem K et al. Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer. Breast J 2012; 18: 535-541
  • 33 Wishart GC, Loh SW, Jones L et al. A feasibility study (ICG-10) of indocyanine green (ICG) fluorescence mapping for sentinels lymph node detection in early breast cancer. Eur J Surg Oncol 2012; 38: 651-656
  • 34 Mieog JS, Troyan SL, Hutterman M et al. Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. Ann Surg Oncol 2011; 18: 2483-2491
  • 35 Solomayer EF, Rody A, Wallwiener D et al. Assessment of university gynaecology clinics based on quality reports. Geburtsh Frauenheilk 2013; 73: 705-712